Flex­ing its new­found wealth, BioN­Tech snaps up a TCR plat­form and man­u­fac­tur­ing site as Gilead ex­its

BioN­Tech is putting some of its new-found wealth from its star mR­NA vac­cine for Covid-19 to use. The biotech $BN­TX, which now weighs in with a be­he­moth $56 bil­lion mar­ket cap, is buy­ing a cell ther­a­py R&D plat­form plus a man­u­fac­tur­ing site from Gilead’s Kite sub.

The deal — which rather odd­ly comes with­out any num­bers from the pub­lic Ger­man biotech com­pa­ny — gives BioN­Tech Kite’s R&D IP for its per­son­al­ized neoanti­gen TCR work as well as the man­u­fac­tur­ing cen­ter it has in Gaithers­burg, MD, which sup­plies clin­i­cal tri­al prod­uct.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER